Delfi Diagnostics’ liquid biopsy test uses machine learning to spot changes in patients’ DNA fragmentation profiles that indicate the presence of cancerous cells.
A new partnership between public and private sector institutions aims to advance the adoption of personalised healthcare in Singapore; part of this includes precision oncology for personalised cancer care.
The Consortium for Clinical Research and Innovation Singapore (CRIS), a wholly owned subsidiary of MOH Holdings, has been established in 2020...
